AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 222 min read$CLDX

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both studies met primary and secondary endpoints, showing significant symptom improvement. The treatment also showed sustained efficacy and a favorable safety profile. CLDX plans to submit a Biologics License Application to the FDA in 2027. Shares initially rose but later fell 12.51% to $36.65.

Original reporting
benzinga.com
Published Sep 22, 2026, 4:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 6:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX) — source image
Source · benzinga.com
Decision brief

The 30-second read

$CLDXBullishMed
01

Why it matters

The data show statistically significant improvements versus placebo, including higher complete response rates and angioedema resolution, positioning the drug for a 2027 BLA filing.

02

Market read

First‑time disclosure of pivotal trial success provides a material catalyst for CLDX and may reshape the CSU therapeutic landscape.

03

What to watch

Reimbursement pathways, pricing pressure, and the long lead time to FDA approval could limit upside.

Relevance 8/10Novelty 9/10Timing: today

Background

Celldex Therapeutics (NASDAQ:CLDX) disclosed topline Phase 3 results for its anti‑IgE antibody barzolvolimab in chronic spontaneous urticaria, a condition with unmet need after antihistamine failure.

Company-level read

Ticker impact

$CLDXBullishHigh confidence
Context

Celldex Therapeutics reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting primary and secondary endpoints and planning an FDA BLA submission in 2027.

Expected impact

Potential upside over the next weeks as investors price in a future FDA filing; short‑term volatility expected.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; market often reacts positively after initial sell‑off.

Market effects

Sector

Strengthens the CSU treatment segment and may pressure competitors like Novartis' Xolair.

Regional

Positive for US biotech equities and related specialty pharma stocks.

Global

Adds a new candidate to the global allergy‑immunology pipeline, potentially influencing worldwide market share.

Counterpoint

What could challenge this read

Despite robust data, the stock fell 12% indicating market skepticism about commercialization risk and timeline.

Key entities

  • company
    Celldex Therapeutics

    Biotech developing barzolvolimab for chronic spontaneous urticaria.

  • company
    Novartis AG

    Manufacturer of Xolair, a competing CSU therapy.

Read at source← All news

Related articles

SEP 22
$CLDXHighAI 8/10

Why is Celldex Therapeutics stock sliding today?

Celldex Therapeutics (CLDX) stock fell 10.4% after Phase 3 trial results for barzolvolimab met primary and secondary endpoints but showed smaller efficacy gains than Phase 2. Analysts maintained positive ratings and price targets. The broader market had minimal impact, highlighting the company-specific move.

investing.com2 min
SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min